Retinalamin polypeptides of the eye retina 5mg x 10pcs
Retinalamin polypeptides of the eye retina 5mg x 10pcs

Retinalamin polypeptides of the eye retina 5mg x 10pcs

select a flag to translate

AfrikaansAlbanianArabicArmenianAzerbaijaniBasqueBelarusianBulgarianCatalanChinese (Simplified)Chinese (Traditional)CroatianCzechDanishDutchEnglishEstonianFilipinoFinnishFrenchGalicianGeorgianGermanGreekHaitian CreoleHebrewHindiHungarianIcelandicIndonesianIrishItalianJapaneseKoreanLatvianLithuanianMacedonianMalayMalteseNorwegianPersianPolishPortugueseRomanianSerbianSlovakSlovenianSpanishSwahiliSwedishThaiTurkishUrduVietnameseWelshYiddishBengaliBosnianKhmerLaoMaoriMongolianNepaliSomali
85.71 $



Share
 

Retinalamin is a complex of water-soluble polypeptide fractions with a molecular weight of no more than 10,000 DA. The drug has a stimulating effect on photoreceptors and cellular elements of the retina, improves the functional interaction of the pigment epithelium and outer segments of photoreceptors, glial cells in dystrophic changes, accelerates the restoration of light sensitivity of the retina. Normalizes vascular permeability, reduces manifestations of local inflammatory reaction, stimulates reparative processes in diseases and injuries of the retina.

Indications for use:
Compensated primary open-angle glaucoma, diabetic retinopathy, central retinal dystrophy of inflammatory and traumatic genesis, central retinal dystrophy, myopic disease (as part of complex therapy), central and peripheral tapetoretinal abiotrophy.

For adults with diabetic retinopathy, central retinal dystrophy of inflammatory and traumatic genesis, central and peripheral tapetoretinal abiotrophy: parabulbar or intramuscularly 5-10 mg once daily. The course of treatment is 5-10 days; if necessary, repeat after 3-6 months. For compensated primary open-angle glaucoma: parabulbar or intramuscularly 5 mg once daily. The course of treatment is 10 days; if necessary, repeat after 3-6 months. For myopia: parabulbar, 5 mg once daily. The course of treatment is 10 days. For children aged 1-5 years with central retinal dystrophy of inflammatory and traumatic genesis, central and peripheral tapetoretinal abiotrophy: parabulbar or intramuscularly 2.5 mg once daily. For children aged 6–18 years with central retinal dystrophy of inflammatory and traumatic genesis, central and peripheral tapetoretinal abiotrophy, parabulbar or intramuscularly 2.5–5.0 mg once daily. The drug is dissolved in 1–2 ml of 0.9% sodium chloride solution, directing the needle toward the wall of the bottle to avoid foaming. The course of treatment is 10 days; if necessary, repeat after 3–6 months.

4607008360028

منتجات تم شراؤها من نفس العملاء:

Product added to wishlist